91934-95-1

Basic information

• Product Name: (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal
• Synonyms: (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal;(5alpha,11beta,17alpha)-11-[4-(Dimethylamino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one cyclic 1,2-ethanediyl acetal
• CAS NO: 91934-95-1
• Molecular Formula: C₃₀H₃₉NO₄
• Molecular Weight: 477.63496
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Steroids.
• Mol File: 91934-95-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal(CAS DataBase Reference)
• NIST Chemistry Reference: (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal(91934-95-1)
• EPA Substance Registry System: (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal(91934-95-1)

Safety Data

• Hazardous Substances Data: 91934-95-1(Hazardous Substances Data)

Usage

Description

(5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal is a complex organic compound with a unique molecular structure. It is characterized by its steroidal backbone and the presence of a cyclic 1,2-ethanediylacetal group. (5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal exhibits specific stereochemistry, with the 5α, 11β, and 17α configurations playing a crucial role in its properties and potential applications.

Uses

Used in Pharmaceutical Industry:
(5α,11β,17α)-11-[4-(diMethylaMino)phenyl]-5,17-dihydroxy-19-norpregn-9-en-20-yn-3-one Cyclic 1,2-Ethanediyl Acetal is used as an intermediate in the synthesis of 17β-side chain mifepristone analogues. These analogues act as progesterone receptor antagonists, which have potential applications in the development of contraceptives and treatments for hormone-dependent disorders.
As a key intermediate in the synthesis of mifepristone analogues, this compound contributes to the advancement of pharmaceutical research and the development of new therapeutic agents. Its unique structure and functional groups enable the design and synthesis of novel compounds with improved pharmacological properties and therapeutic potential.

Upstream product

• 586-77-6 4-bromo-N,N-dimethylaniline 
• 137532-55-9 3-(ethylenedioxy)estra-5α,10α-epoxy-17α-ethynyl-17β-hydroxy-9(11)-ene 
• 39931-88-9 (5'R,10'R,13'S)-13'-methyl-1',2',6',7',8',12',13',14',15',16'-decahydro-17'H-spiro[1,3-dioxolane-2,3'-[5,10]epoxycyclopenta[a]phenanthren]-17'-one 
• 5571-36-8 ethylene deltenone 
• 5173-46-6 4,9-Androstadiene-3,17-dione 
• 5490-76-6 (8S,13S,14S,17R)-17-ethynyl-13-methyl-1,2,4,6,7,8,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2’-[1,3]dioxolan]-17-ol 
• 786698-67-7 3-(ethylenedioxy)estra-5,10-epoxy-9⁽¹¹⁾-ene-17-one 

Downstream Products

• 196881-37-5 C₃₇H₄₅NO₆S 
• 948907-54-8 3,3-ethylenedioxy-5α,17β-dihydroxy-11β-[4-(N,N-dimethylamino)phenyl]-19-nor-17α-pregn-9-ene-21-ethynyl phosphonic acid diethyl ester 
• 159811-51-5 CDB-3236 
• 126784-99-4 ulipristal acetate 

Relevant articles and documents

Acetic acid wu lisi he and its intermediate preparation method

The invention discloses a preparation method of ulipristal acetate and an intermediate thereof, and belongs to the field of pharmaceutical synthesis. The preparation method of the ulipristal acetate comprises the following steps: by taking 3,3-(ethylenedioxy)-19-methylestra-5(10),9(11)-diene-3,17-diketone as raw material, enabling the raw material to react with sodium acetylide or potassium acetylide to obtain a compound III, carrying out high-selectivity epoxidation by oxide to obtain a compound IV, subsequently enabling the compound IV to react with 4-(N,N-dimethyl amino) phenyl magnesium bromide Grignard reagent to obtain a compound V, then enabling the compound V to react with phenyl sulfonic acid chloride to obtain a compound VI, enabling the compound VI to respectively react with sodium methoxide and trimethyl phosphate to obtain a compound VII, hydrolyzing and removing a protection group to obtain a compound VIII, finally carrying out acetylation reaction to obtain the ulipristal acetate, wherein the reaction formulae are as shown in the description. The method is short in synthetic route, mild in reaction conditions, high in yield and purity of products, low in cost, stable and controllable in quality, and is suitable for industrial production.

Novel phosphorus-containing 17β-side chain mifepristone analogues as progesterone receptor antagonists

A novel series of steroidal compounds were designed and synthesized with various phosphorus-containing groups on the 17β-side chain as progesterone receptor antagonists. The structure-activity relationships of these compounds are discussed. Selected compo